Evidence map›Paper›PMID 41850678›Full record

ArticleCellular and molecular gastroenterology and hepatology2026

Interleukin 6 Drives Durable T Cell-Mediated Immunity to Pancreatic Cancer.

Paige C Arneson-Wissink, Alexandra Q Bartlett, Heike Mendez, Xinxia Zhu, Peter R Levasseur, Parham Diba, Namratha Turuvekere Vittala Murthy, Jessica Dickie, Matthew McWhorter, Antony Jozic and 6 more

Abstract read
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Interleukin-6: The Unexpected Opponent to Pancreatic Cancer.Cellular and molecular gastroenterology and hepatology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Paige C Arneson-WissinkDepartment of Radiation Medicine, Oregon Health and Science University, Portland, Oregon.
Alexandra Q BartlettDivision of Surgical Oncology, Department of Surgery, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
Heike MendezDepartment of Radiation Medicine, Oregon Health and Science University, Portland, Oregon.
Xinxia ZhuDepartment of Radiation Medicine, Oregon Health and Science University, Portland, Oregon.
Peter R LevasseurDepartment of Radiation Medicine, Oregon Health and Science University, Portland, Oregon.
Parham DibaDepartment of Radiation Medicine, Oregon Health and Science University, Portland, Oregon; Medical Scientist Training Program, Oregon Health and Science University, Portland, Oregon.
Namratha Turuvekere Vittala MurthyDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon.
Jessica DickieDepartment of Radiation Medicine, Oregon Health and Science University, Portland, Oregon.
Matthew McWhorterDivision of Surgical Oncology, Department of Surgery, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
Antony JozicDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon.
Yulia EygerisDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon.
Gaurav SahayDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon; Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon.
Katelyn T ByrneDepartment of Cell, Development, and Cancer Biology, Oregon Health and Science University, Portland, Oregon; Brenden Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, Oregon.
Gregory D ScottDepartment of Pathology, Oregon Health and Science University, Portland, Oregon.
Robert EilDivision of Surgical Oncology, Department of Surgery, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
Aaron J GrossbergDepartment of Radiation Medicine, Oregon Health and Science University, Portland, Oregon; Department of Cell, Development, and Cancer Biology, Oregon Health and Science University, Portland, Oregon; Brenden Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, Oregon; Cancer Early Detection Advanced Research Center, Oregon Health and Science University, Portland, Oregon. Electronic address: grossber@ohsu.edu.

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Mechanistic insights on structure, topology and radiation effects on RNA nanomedicinesR01CA270783 · NCI · OREGON STATE UNIVERSITY · PI Gaurav Sahay, Conroy Ghin Chee Sun · 2023 to 2026
$2.2M
PQ6: Therapeutic approaches for autonomic and neuroendocrine dysfunction in cancer cachexiaR01CA264133 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GROSSBERG, AARON · 2021 to 2025
$2.1M
Metabolic vulnerability due to dysregulated lipid metabolism in PDAC cachexiaR37CA280692 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Aaron Grossberg · 2023 to 2026
$1.5M
Targeting an unrecognized checkpoint on T cell function in tumorsK08CA256179 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI EIL, ROBERT LANGLAND · 2021 to 2025
$1.2M
Hepatic metabolic reprogramming drives pancreatic cancer cachexiaK08CA245188 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GROSSBERG, AARON · 2020 to 2024
$1.2M
Elucidating the role of hepatic ketogenesis in pancreatic cancer cachexia and recoveryK99CA286709 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI ARNESON-WISSINK, PAIGE C · 2024 to 2025
$236k
NCI NIH HHS K08 CA245188NCI NIH HHS K08 CA256179NCI NIH HHS K99 CA286709NCI NIH HHS P30 CA069533NCI NIH HHS R01 CA264133NCI NIH HHS R01 CA270783NCI NIH HHS R37 CA280692
6 · The paper itself

Abstract

BACKGROUND &

aimsTumor immune resistance is recognized as a contributor to low survivorship in pancreatic ductal adenocarcinoma (PDAC). The inflammatory cytokine interleukin-6 (IL-6) promotes polarization of CD4 T cell populations away from immune tolerance, and induces differentiation of cytotoxic CD8 T cells. This work aims to test whether IL-6 could stimulate an anti-tumor response in PDAC

methodsWe overexpressed IL-6 in multiple Kras

resultsImproved survival occurred in all instances of OT-PDAC

conclusionsLocally high IL-6 concentrations potently enhance the T cell-mediated anti-tumor response to PDAC.

Indexed as

Carcinoma, Pancreatic DuctalImmunity, CellularInterleukin-6Pancreatic NeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMiceMice, Inbred C57BLInterleukin-6Interleukin 6Pancreatic Ductal AdenocarcinomaT Regulatory Cells

Identifiers

PMID41850678
PMCPMC13158792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.